BioPharma companies and Medical Device manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.
The traditional clinical development model needs to change.
The traditional healthcare delivery model is changing.
Technologies that accelerate and improve Clinical Trials.
Patients are now better informed on clinical options than they ever have been.
An end-to-end approach to managing wearable devices through clinical development.
Find out more about estimands and how deploying this approach will improve the quality of clinical research.
Insights to maximise HTA success.
The patient perspective.
Best practices to accelerate operations while the world waits.
ICON conducted a survey through its Global Site Network to get the patient view.
In-depth interviews reveal what manufacturers can expect from US payers.
Why outsourcing pharmacovigilance make sense at an affiliate level
Discover how emerging technologies can increase clinical trial efficiency
Harnessing the power of digital technologies.
Perspectives from senior pharma executives
Engage assay experts with unparalleled experience and expertise
Understanding the challenges for formulary decision makers and manufacturer
Determine the right design, assessments and endpoints in your pain study
Develop the right business strategy to successfully navigate MDR/IVDR
primary research evaluating ICER’s influence over payers and manufactures
Increasing efficiency through automation
Develop an integrated, patient centric approach to harnessing Digital Health technologies
Get the insights you need for successful biosimilar commercialisation
Global Investigator Payments Solutions
ICON’s monthly Regulatory Intelligence Newsletter
Legacy Data Conversion
Remote monitoring and leveraging wearable devices and sensors in clinical trials.
An adaptive design clinical trial can help to create a stronger value proposition for your medical device by reducing development costs and accelerating time-to-market.